Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fovista + bevacizumab
- Development stage
- Unknown
- Lead developer
- Astellas Pharma
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
Fovista + bevacizumab is an investigational combination therapy for neovascular (wet) age-related macular degeneration (AMD). Fovista (pegpleranib, also known as E10030) is a pegylated aptamer that targets and inhibits platelet-derived growth factor-BB (PDGF-BB), disrupting pericyte support of abnormal blood vessels. Bevacizumab is a monoclonal antibody that binds to and neutralizes vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis. The rationale for combining these agents is to simultaneously block two key pathways involved in the formation and maintenance of abnormal choroidal neovascularization in wet AMD—VEGF-driven endothelial cell proliferation/leakage and PDGF-mediated pericyte recruitment/stabilization. Clinical trials have evaluated this combination to determine if dual inhibition offers superior visual outcomes compared to anti-VEGF monotherapy[2][3][4][5][6].
- Brand names
- Fovista + Avastin
- Other names
- anti-PDGF aptamer (Fovista) plus anti-VEGF antibody (bevacizumab)
02
Targets
VEGFA (Vascular endothelial growth factor A)PDGFB (PDGF-B)
Beyond the preview
Go deeper on fovista + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fovista + bevacizumab.